News coverage about Regenxbio (NASDAQ:RGNX) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regenxbio earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.2596122285121 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Regenxbio (NASDAQ:RGNX) traded up $0.30 during trading on Friday, reaching $27.85. The company’s stock had a trading volume of 149,407 shares, compared to its average volume of 245,921. The company has a market capitalization of $867.39, a PE ratio of -10.31 and a beta of -1.30. Regenxbio has a 52-week low of $16.30 and a 52-week high of $36.45.
Several brokerages recently commented on RGNX. Mizuho began coverage on Regenxbio in a research note on Monday, February 12th. They issued a “neutral” rating and a $28.00 price target for the company. BidaskClub raised Regenxbio from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. ValuEngine cut Regenxbio from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Chardan Capital boosted their price target on Regenxbio from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Finally, TheStreet cut Regenxbio from a “c” rating to a “d+” rating in a research note on Tuesday, November 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $40.63.
In other Regenxbio news, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $26.56, for a total transaction of $265,600.00. Following the completion of the sale, the insider now owns 238,530 shares of the company’s stock, valued at $6,335,356.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Curran Simpson sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $29.31, for a total value of $58,620.00. Following the sale, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at approximately $1,216,365. The disclosure for this sale can be found here. Insiders have sold 94,000 shares of company stock valued at $2,867,596 in the last ninety days. Company insiders own 17.00% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.